$21.53—
Real-time prices · US MarketsClean balance sheet with low leverage (0.0× debt-to-equity).
currently unprofitable (-68% margin).
Quality
0.5
Health
9.2
Growth
7.3
Valuation
3.7
Sentiment
2.5
Analyst Target
$21.50
▼ 0.1% from current
Price Chart
Data not available.
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-112.4×
next 12 months est.
Market Cap
$2.2B
market capitalization
Div Yield
—
dividend yield
Profit Margin
-67.8%
net profit margin
Gross Margin
89.1%
revenue minus COGS
ROE
-22.7%
return on equity
Beta
-1.75
vs S&P 500
52-Week Range
$6 — $22
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Day One Biopharmaceuticals, Inc right now?
Day One Biopharmaceuticals, Inc's Q·Score is 4.5/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: currently unprofitable (-68% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for DAWN?
The consensus price target for DAWN is $21.50, based on ratings from 6 Wall Street analysts. This is 0.1% below the current price of $21.53. Price targets are forward-looking estimates and not guarantees of future performance.
Is DAWN overvalued or undervalued?
Day One Biopharmaceuticals, Inc (DAWN) scores below peers on valuation metrics, trading above typical sector multiples.
What is Day One Biopharmaceuticals, Inc's profit margin?
Day One Biopharmaceuticals, Inc has a net profit margin of -67.8%, indicating the company is currently operating at a net loss. Its gross margin stands at 89.1%, indicating a high-margin business model.
Is Day One Biopharmaceuticals, Inc's revenue growing?
Day One Biopharmaceuticals, Inc is reporting strong year-over-year growth of 83.9%.
How much debt does Day One Biopharmaceuticals, Inc have?
Day One Biopharmaceuticals, Inc has a debt-to-equity ratio of 0.01×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 8.02×, indicating comfortable short-term liquidity.